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1. Introduction
The past two decades have witnessed an unprecedented level of attention devoted to the as‐
sessment of Quality of Life (QOL) in cancer patients. This is a result of a major change that
occurred in the way cancer management and its impact has been understood and practiced.
Contrary to earlier views, which focused primarily on prolonging the quantity of life of the
patient, cancer management recognizes now the potential effects of the diagnosis and treat‐
ment on the overall functioning and well-being of the patient. QOL issues and its measure‐
ment became particularly important in oncology throughout the different phases of the
cancer trajectory. In this context, the National Cancer Institute (NCI) has recommended that
cancer research focus on both survival and QOL [1]. Many instruments have been devel‐
oped and used in clinical and research settings. It is noteworthy the inclusion of QOL as one
of the main endpoints in important randomized clinical trials [2]. The benefits of studying
QOL outcomes are evident. Primarily, QOL measurement has the potential to provide infor‐
mation to guide clinical decision making [3]. The knowledge about the impact of the illness
and its treatment on cancer patients can help clinicians and patients to make decisions re‐
garding treatment options and choose appropriate supportive therapy adjusted to the pa‐
tient's needs. The toxicity and tolerability of a given treatment can be as important as its
efficacy, as is the ability to help decrease or prevent associated toxicities that have a negative
impact on QOL [4]. Furthermore, QOL data can foster patient-clinician interactions in rou‐
tine practice, identify problems that have a significant impact on QOL, prioritize problems,
develop interventions to deal with these problems and evaluate the impact of palliative and
rehabilitative efforts [5]. Additionally, it can help to shape public policy and health care de‐
cisions made by governmental and private institutions [6] and allow the economic evalua‐
tion of healthcare provision [7].
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When considering ovarian cancer in particular, researchers follow the general trend by re‐
garding QOL as one of the most important outcomes. Several reasons make the study of
QOL in ovarian cancer patients especially worthy and relevant. First, ovarian cancer is an
aggressive illness which is associated with very poor survival and high recurrence rates. It is
the most fatal malignancy of the female genital tract and the fourth most common cause of
female cancer death [8]. Generally, it is detected at an advance stage, with a 5-year survival
rate of 46% for all the stages and 31% for advanced stages [8]. The management of ovarian
cancer normally includes radical pelvic surgery and multiple aggressive courses of chemo‐
therapy. The stress of receiving the diagnosis of such an aggressive and life threatening ill‐
ness, which can be unexpected for many women, may be associated with uncertainty and
anxiety about the future. This may be regarded as an immediate threat to a woman's life and
an associated fear of death. Additionally, women may suffer disease-related symptoms,
which may be very difficult to cope with. These include weight loss, bloating and ascites,
fatigue and pain. Women may also experience a wide range of sequalae related to their
treatment that do not dissipate with time and may persist for a long-term period [9, 10]. Ex‐
amples include neutropenia, body distortion, hair loss, bowel and bladder incontinence, loss
of taste and appetite, premature menopause, infertility, decrease physical functioning, poor
sleep, edema and sexual problems [9, 10]. Another burden involves the amount of time
spend in treatments that is lost from family and work [11]. Second, research carried out, spe‐
cifically, with ovarian cancer patients has shown that a substantial proportion of women ex‐
perience psychological disorders. Anxiety, depression [9, 12-16] and Post-Traumatic Stress
Disorder (PTSD) [17] have been found among different studies. Reports have also highlight‐
ed the occurrence of impairments in physical, vocational, social, familial and sexual func‐
tioning. Those are not confined to the diagnosis and treatment periods, but have been also
observed in short and long-term ovarian cancer survivors. Lastly, advances in Medicine fu‐
elled the development of new treatments for ovarian cancer. However, these treatments
have associated side-effects and toxicities that may impact on the QOL of the women. There‐
fore, when considering a treatment plan, risks and benefits must be balanced in order to
achieve an optimal QOL [11]. Improvements in survival in ovarian cancer have been rela‐
tively reduced [18]. The ability of chemotherapeutic regimens in slowing the progression of
disease to prolong life with active disease has been responsible for those improvements in
survival [19]. Undoubtedly, QOL is a fundamental consideration for patients with ovarian
cancer.
This chapter addresses the most recent knowledge regarding the impact of the treatment
on QOL of ovarian cancer patients. Additionally, QOL in ovarian cancer survivors is al‐
so discussed.
2. Quality of life: Brief overview
Central to this particular subject, is the question: What is QOL? Although, it is somehow
consensual by the clinical and research communities the importance of studying QOL, it is
much less consensual what exactly QOL means. This lack of consensus fuels the appearance
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of different definitions and, inevitably, means of measurement. This makes difficult the
comparison of findings among studies and to establish more definite conclusions. Issues of
definition and measurement continue to be, in fact, the subject of ongoing debate. Despite
lack of consensus in its definition, it is widely accepted that QOL is a multidimensional con‐
struct that includes several important dimensions (any area of behavior or experience) [4, 7,
20, 21]. These encompass physical functioning (physical well-being, mobility, ability to per‐
form self-care activities, physical activities, role activities such as work or housework, appe‐
tite, comorbidities, fatigue/sleep, symptoms, side-effects), cognitive and psychological
functioning (emotional well-being, anxiety, depression, coping, perceptions, prior experi‐
ence, enjoyment, optimism), social functioning (family interactions, time with friends, lei‐
sure activities), disease and treatment related symptoms (such as pain and fatigue), spiritual
or existential concerns, sexual functioning, body image, patient's satisfaction with health
care, control of the disease [7, 21]. According to the WHO [22], QOL is defined as 'an indi‐
vidual's perception of their position in life in the context of the culture and value systems in
which they live and in relation to their goals, expectations, standards and concerns. It is a
broad ranging concept affected in a complex way by the person's physical health, psycho‐
logical state, level of independence, social relationships, and their relationships to salient
features of their environment". Following these lines, QOL includes all aspects of the indi‐
vidual well-being and must be evaluated from the individual's perspective.
When QOL is considered in the context of health, it is often referred to as health-related
QOL (HRQOL). HRQOL is a more specific concept, which reflects the effect of the illness
and illness treatment on general well-being. Bowling defined HRQOL as ‘optimum levels
of mental,  physical,  role (e.g.  work, parent,  career,  etc) and social functioning, including
relationships, and perceptions of health, fitness, life satisfaction and well-being. It should
also  include  some assessment  of  patient´s  level  of  satisfaction  with  treatment,  outcome
and health status and with future prospects.  It  is  distinct  from QOL as a whole,  which
would also include adequacy of housing, income and perceptions of immediate environ‐
ment’ [23]. HRQOL is a dynamic concept, as health status deteriorates, experiences, roles
and  relationships  change  [24].  Furthermore,  It  may  be  modified  by  impairments,  func‐
tional  status,  perceptions,  and  social  opportunities  and  may  be  influenced  by  disease,
treatment, and policy [25].
Particularly in ovarian cancer literature, the term QOL is much more extensively used in‐
stead of HRQOL. In general, QOL assessment in ovarian cancer patients has been focusing
more on the acute phase of the treatment. Of interest is the evaluation of QOL under treat‐
ment conditions in randomized clinical trials, focusing on different treatment options. The
measurement of QOL in screening and early diagnosis of ovarian cancer is very scarce. It of
note that, in fact, screening and early detection of ovarian cancer are very limited in clinical
practice, existing narrow useful technologies to assist in early diagnosis. The majority of the
QOL measurement in ovarian cancer screening evaluates populations at high risk, such as
women with genetic mutations undergoing risk-reducing salpingo-oophorectomy [26].
However, for individuals undergoing risk-reducing salpingo-oophorectomy, screening is
more a process of early detection or diagnosis rather than a true screening test [26]. Regard‐
Quality of Life in Ovarian Cancer Treatment and Survivorship
http://dx.doi.org/10.5772/54542
29
ing survivorship, recently, there is a growing interest in the study of QOL in ovarian cancer
survivors. The following section focuses on the instruments designed to capture QOL that
are more commonly used in this specific population.
3. Measurement of QOL in patients with ovarian cancer
Many instruments have been developed and validated to capture important QOL issues in
cancer patients. These instruments comprise four main groups: generic measures of QOL
(used to assess non-cancer medical patients), cancer condition-specific (used in general can‐
cer populations), cancer site and treatment-specific instruments. QOL measures are often
supplemented by questionnaires designed to evaluate specific dimensions of QOL, for ex‐
ample depression. The use of generic questionnaires allows comparisons of QOL among
conditions [7]; however, they lack specificity necessary to understand particular problems
inherent to a specific condition, such as cancer. This specificity can be found when disease –
and site-specific instruments are used. These are more likely to be responsive to change but
are not comprehensive [7]. The Medical Outcome Study (Short Form) MOS SF-36 [27] is an
example of a QOL generic instrument used in oncology. The European Organization for Re‐
search and Treatment of Cancer QOL Core Questionnaire (EORTC QOL-C30) [28] and the
Functional Assessment of Cancer Therapy – General (FACT-G) [20] are examples of condi‐
tion (cancer) specific instruments. All are self-administered questionnaires, multidimension‐
al, relatively brief, acceptable to patients and have good psychometric properties [7]. The
EORTC QOL-C30 and the FACT-G comprise ovarian cancer modules that constitute exam‐
ples of site specific QOL instruments.
Particularly in ovarian cancer, the most commonly used measures are the EORTC QOL-C30
and the FACT-G [18]. The EORTC QOL-C30 and the FACT-G have a similar format: a core
QOL questionnaire applicable to cancer patients in general and specific modules, applicable
to specific cancer sites. These instruments have been developed primarily from research en‐
vironments; however, they will be extremely helpful if they assist physicians in detecting
clinically significant differences or changes in a patient condition.
3.1. EORTC QOL-C30
This cancer-specific questionnaire was developed by the Study Group on Quality of Life
from the European Organization for Research on Treatment of Cancer comprising a core set
of questions applicable to all cancer patients and modules to be used to specific cancer sides,
such as ovarian cancer [28, 29]. This instrument was designed to be used in international
randomized clinical trials. It is based on a multidimensional model of QOL, covering cancer-
specific symptoms of the disease, psychological distress, treatment side-effects, social inter‐
action, physical functioning, body image, sexuality, global health and QOL, and satisfaction
with medical care. The core QOL instrument is composed by 30 items, comprising nine
scales of QOL: one global QOL scale (2 items), five functional scales (physical functioning,
role functioning, cognitive functioning, emotional functioning, social functioning) (15 iems),
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three symptom scales (fatigue, pain, nausea and vomiting) (7 items), and six single items,
assessing additional symptoms commonly reported by cancer patients (breathlessness, diffi‐
culty sleeping, appetite loss, constipation, diarrhea, and financial difficulties). Each scale is
scored separately. Seven questions have a dichotomous yes/no response. For the two global
QOL items, respondents have to answer by using a 7-point scale, where '1 = very poor' and
'7 = excellent'. The remaining questions have a four-point Likert scale, ranging from '1 = Not
at all' to '4 = Very much'. No timeframe is specified in the seven dichotomous questions. In
the remaining questions, the patient has to answer according to the past week. Each dimen‐
sion score for each patient is the sum of that patient's item responses for that dimension,
transformed, so that the minimum possible value is zero and the maximum possible value is
100. Each scale has a limited set of possible values, determined by the number of items and
the range of response options for each item. For the functional scales and the global QOL
scale, a higher score corresponds to a better QOL. For the symptom scales and the single
items, a higher score indicates more frequent and/or intense symptom experience and thus a
lower QOL. Finally, there are two items that ask respondents to rate their overall physical
condition. The EORTC QOL-C30 has established reliability and validity [28]. This scale is
easy to complete, acceptable to patients and has been translated into several languages. The
EORTC QOL-OV28 is the ovarian cancer module designed to supplement the EORTC QOL-
C30, for the assessment of QOL in ovarian cancer patients in clinical trials and related stud‐
ies. It consists of 7 subscales and a total of 28 items, which assess abdominal symptoms
(abdominal pain, feeling bloated, clothes too tight, changed bowel habit, flatulence, fullness
when eating, indigestion), peripheral neuropathy (tingling, numbness, and weakness), other
chemotherapy related side effects (hair loss and upset by hair loss, taste change, muscle
pain, hearing problem, urinary frequency, and skin problem), hormonal/menopausal symp‐
toms (hot flushes and night sweat), body image (less attractive, dissatisfied with body), atti‐
tude to disease and treatment (disease burden, treatment burden, and worry about future)
and sexual functioning (interest in sex, sexual activity, enjoyment of sex and dry vagina) [29,
30]. Each scale is scored separately. For symptom scales, a higher score means a lower QOL,
while for function scales, such as body image and sexual function, a higher score means a
better QOL. The EORTC QOL-OV28 is a valid and reliable measure to be used in ovarian
cancer populations [30].
3.2. FACT-G
The FACT-G was developed by Cella et al to evaluate QOL in oncology settings [20]. This is
the core scale of the instrument system and consists of four dimensions, comprising a total
of 27 items. The dimensions include functional well-being (7 questions), emotional well-be‐
ing (6 questions), social/family well-being (7 questions) and physical well-being (7 ques‐
tions). These four dimensions can be analyzed separately or aggregated to produce a total
QOL score. Response categories for all items range from 0 (not at all) to 4 (very much).
Higher scores are associated with increased satisfaction with QOL. The timeframe for this
instrument is the past 7 days. FACT-G is tested and validated in large international samples,
showing reliability, validity and responsiveness to change over time [20]. This instrument is
commonly used in ovarian cancer clinical trials and it is available in many languages. The
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supplement of the FACT-G with a set of twelve items specific to ovarian cancer is referred as
the Functional Assessment of Cancer Therapy – Ovarian (FACT-O). Items include stomach
swelling, losing weight, bowels control, vomiting, hair loss, appetite, appearance, getting
around, feeling like a woman, stomach cramping, interest in sex and concerns about ability
to have children. The ovarian cancer specific subscale assesses severity of problems that can
be targeted by proper disease management. The FACT-O is a valid instrument to be used in
ovarian cancer patients [31]. This questionnaire has been commonly used in clinical trials
and other descriptive studies. The FACT-O can be used alone or in combination with other
scales or subscales of the FACT, such as the FACT/GOG neurotoxicity subscale, or the Ane‐
mia (FACT-An) or Fatigue (FACT-F) subscale, if the research interest is these specific issues.
The physical well-being and the functional well-being scales of the FACT-G plus the ovarian
cancer subscale can be combined to represent the Trial Outcome Index (TOI). This index has
excellent psychometric properties [31].
4. Quality of life in ovarian cancer patients
How is the QOL of ovarian cancer patients? Do patients with ovarian cancer experience a
good QOL? These are questions that researchers have been attempting to answer in the
many studies available dedicated to this subject. The number of studies carried out in‐
creased significantly in recent years [18], and collectively, these studies captured ongoing is‐
sues and concerns resulting from the ovarian cancer diagnosis and treatment [9]. However,
there is a difficulty in drawing definite conclusions to answer the above questions. This is
due to the lack of consistency in the types and format of QOL data collected in ovarian can‐
cer patients [18]. The accumulated knowledge about QOL issues in patients undergoing
treatment and in survivors of ovarian cancer is presented below.
4.1. QOL during ovarian cancer treatment
The management of ovarian cancer generally requires a multimodal approach. Surgery has
always been the cornerstone, which plays an essential role in both diagnosis and treatment.
The aim of which is to leave no residual deposits greater than 1–2 cm in diameter. In cases of
apparent early stage disease, proper surgical management involves comprehensive surgical
staging. Advanced-stage disease frequently requires aggressive surgical debulking [32]. The
standard approach is to follow surgery by either intravenous or intraperitoneal chemothera‐
py. Two classes of cytotoxic components, the plantinums and the taxanes are key compo‐
nents of chemotherapeutic regimens for advanced disease [33]. Both treatment modalities
can impact negatively on the QOL of patients [34]. In recurrent disease, a variety of treat‐
ment regimens are used, including re-treatment with a platinum and/or taxane agent, and
second line agents such as liposomal doxorubicin, topotecan, and gemcitabine. Chemothera‐
py side effects may be temporary (e.g. hair loss, nausea and vomiting) or cumulative and/or
permanent (e.g. fatigue, neurotoxicity) [34].
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It is paramount to understand how ovarian cancer and its treatment may disrupt the overall
well-being and QOL of patients. A recent systematic review and meta-analysis, carried out
to assess and summarize QOL data before, during and after chemotherapy among ovarian
cancer patients, found that baseline QOL may significantly improve, particularly after com‐
pletion of chemotherapy treatment [18]. Authors identified a total of 139 studies; of those, 48
were randomized clinical trials. However, it was only possible to synthesize data from a
subset of studies, due to inconsistencies in the way the data was reported across studies.
Pooled data showed that QOL as measured by the EORTC QOL C-30 was found to improve
during the treatment period and ovarian cancer specific concerns as measured by the FACT-
O subscale, were improved during the treatment period [18]. The EORTC QOL C-30, FACT-
G and FACT-O found significant improvements in QOL after completion of primary
therapy, despite the lack of measurable improvements during treatment as measured by the
FACT-G [18]. Following these lines, a recent longitudinal study evaluated the course of
QOL, depressive symptoms, anxiety symptoms and fatigue over the course of chemothera‐
py until 6 months follow-up [35]. Results demonstrated a significant improvement of QOL,
as measured by the EORTC QOL C-30 and EORTC QOL OV-28, from the start of chemother‐
apy and post-surgery period (QOL was severely impaired and high levels of anxiety symp‐
toms, depressive symptoms and fatigue were found), until after care (symptoms reach
nearly general population symptom levels). Although, this was a small study of 23 patients,
it highlighted the importance of understanding QOL over the course of treatment [35]. Simi‐
lar results were obtained by other investigators, reporting improvements of QOL in ovarian
cancer during chemotherapy until one year follow-up. Von Gruenigen et al [36] in a sample
of 42 ovarian cancer patients found that QOL, as measured by the FACT-G and SF-36, mark‐
edly decreased after surgery with a slow improvement during adjuvant chemotherapy,
mainly in the physical, functional and fatigue domains. Physical functioning decreased dur‐
ing chemotherapy but increased to perioperative levels following treatment. Functional
well-being increased following chemotherapy, while emotional and social scores did not
change over time [36]. Collectively, these findings highlight that, in addition to chemothera‐
peutic treatments, surgery may have a negative impact on QOL. Although several factors
may influence this impact, tumour stage, and therefore, the extent of the surgical interven‐
tion and the existence of intra – or postoperative complications may be crucial [35]. Minig et
al [37] found in a study of 181 women with gynaecological cancers, of which 116 had ovari‐
an cancer, that postoperative complications, surgical complexity, advanced stage were asso‐
ciated with lower levels of postsurgical QOL specifically in ovarian cancer patients. The
strongest predictor of postsurgical QOL was preoperative QOL, closely followed by surgical
complications. Investigators stressed that postoperative complications may be difficult to
avoid due to the aggressiveness of the surgery performed in order to achieve maximum cy‐
toreduction in ovarian cancer; however, attention needs to be paid intraoperatively and
postoperatively to the early detection of complications to optimize QOL whenever possible
in this group of patients [37]. Consequences of surgery are well documented, including loss
of fertility, sexual dysfunction, surgical menopause and bowel obstruction. For women at re‐
productive age, premature menopause and loss of fertility may be devastating [34].
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Several clinical trials evaluating ovarian cancer treatments have been carried out, in which
QOL is one of the outcomes evaluated. Table 1 describes recent clinical trials that have in‐
cluded QOL as an outcome. QOL measurement in clinical trials has been useful to argue in
favor or against novel therapies. Furthermore, there is some evidence demonstrating that
QOL is a prognostic indicator for treatment outcomes [26] and future survival [38-41].
Study Comparison Group QOL measures QOL findings
GOG-17242 Intraperitoneal (IP) versus
intravenous (IV) therapy for
first line therapy
FACT-TOI
Neurotoxicity and
abdominal discomfort
subscales
During active treatment,
patients on IP had more
QOL disruptions when
compared to IV therapy
SCOTROC43 Carboplatin docetaxel
compared with carboplatin
paclitaxel for first line
therapy
EORTC QOL-C30
EORTC QOL-OV28
Global QOL scores did not
differ between treatment
arms. Less neurotoxicity
was found in the docetaxel
group
Vergote (2010)44 a
Gynecologic Cancer
Intergroup Collaboration
Trial
Neoadjuvant
chemotherapy versus
primary surgery in stages
IIIC or IV
EORTC QOL-C30
EORTC QOL-OV28
No differences in global
health scores
OVAR 345 Cisplatin/paclitaxel versus
carboplatin/paclitaxel for
first line therapy
EORTC QOL-C30 Higher QOL with
carboplatin/paclitaxel
Ferrandina (2008)46
Multicenter Italian Trials in
ovarian Cancer group
Pegylated doxorubicin
versus gemcitabine for
progressive or recurrent
disease
EORTC QOL-C30 Higher QOL in the
pegylated doxorubicin arm
OV-0547 Early versus delayed
treatment for recurrent
disease
EORTC QOL-C30 QOL decreased shorter in
the early treatment arm;
significant disadvantages in
role, emotional, social and
fatigue subscales
Table 1. Some recent clinical trials that have included QOL as an outcome
The aggressiveness of  treatments  in advanced ovarian cancer patients  place more atten‐
tion upon their QOL than patients diagnosed at an early stage. Several randomized clini‐
cal trials have been conducted in the first-line treatment of ovarian cancer. Clinical trials
focus in important issues concerning the combination of surgery and chemotherapy, the
identification of new targeted therapeutics and the route and timing of chemotherapy ad‐
ministration  [48].  Paclitaxel  in  combination  with  a  platinum compound is  considered  a
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standard care as first-line chemotherapy for advanced ovarian cancer. However, paclitax‐
el  is  associated  with  several  toxicities  (e.g.  anemia,  thrombocytopenia)  that  overlap  the
toxicities of the plantinums, and the co-administration of paclitaxel and a platinum com‐
pound can potentially  increase  the  frequency and/or  severity  of  shared toxicities.  By it‐
self,  paclitaxel  is  associated  with  peripheral  neuropathy  that  can  add  to  the  disease
burden of the patient [4].  Therefore,  studies have been conducted to find the least toxic
combination of medications used in chemotherapy in order to improve treatment tolera‐
bility and QOL [49]. For example, a Phase III Trial conducted by the Scotish Gynaecolog‐
ical  Cancer  Trials  Group  (SCOTROC  Trial),  which  included  1077  patients,  compared
carboplatin  docetaxel  with  carboplatin  paclitaxel  for  first  line  therapy.  Results  demon‐
strated  a  clear  advantage  for  docetaxel  in  terms  of  neurotoxicity  [43].  Concurrent  with
the  developments  in  intravenous  treatment,  intraperitoneal  treatment  has  also  been
shown  a  valuable  strategy.  The  Gynecologic  Oncology  Group  published  data  from  the
GOG  randomized  phase  III  trial  (GOG  172)  pertaining  QOL  outcomes  associated  with
the use of  intravenous paclitaxel  plus intraperitoneal  cisplatin plus paclitaxel,  versus in‐
travenous  paclitaxel  plus  cisplatin,  for  advanced  stage  cancer  [42].  This  was  the  first
Phase III GOG ovarian cancer that proposed a change in route for the administration of
front-line  chemotherapy.  In  the  intraperitoneal  arm,  overall  survival  was  improved  by
approximately  16  months;  however,  during  active  treatment,  patients  reported  more
QOL disruptions, abdominal discomfort and neurotoxicity compared to those patients re‐
ceiving  conventional  intravenous  chemotherapy.  However,  only  neurotoxicity  remained
significantly higher for patients in the intraperitoneal arm 12 months post-treatment. Fu‐
ture studies to lessen the added burden associated with intraperitoneal therapy are going
[42].  Recently,  Vergote  et  al.  [44]  reported  the  results  of  a  Gynaecologic  Cancer  Inter‐
group Collaboration Trial which compared upfront debulking followed by chemotherapy
to neoadjuvant chemotherapy. This was the first  randomized Phase III  Trial  of neoadju‐
vant chemotherapy in ovarian cancer using QOL as an endpoint. The two groups report‐
ed similar survival outcomes. QOL scores did not differ among the two groups [44].
The majority of ovarian cancer patients will eventually relapse. In fact, it is not uncommon
for ovarian cancer patients to undergo numerous chemotherapeutics treatments. In this con‐
text, the evaluation of QOL is of utmost importance. In the management of recurrent ovari‐
an cancer, tumour control without compromising QOL should be the goal of the therapy
[50]. However, there are deficits in the measurement of general QOL data in the recurrent
setting, in terms of QOL disruptions and number of studies including QOL measurements
[26]. A recent trial published data pertaining the impact of early versus delayed treatment of
recurrent ovarian cancer based on Ca125 measurements exceeding twice the upper limit of
normal. Results showed that women did not live longer if chemotherapy was initiated earli‐
er based on Ca125, as opposed to delaying treatment until symptoms developed. In addi‐
tion, QOL was higher in women who underwent treatment at the time of clinical recurrence
[47]. Despite the limitations of this study, these findings may have potential impact on clini‐
cal practice.
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4.2. QOL in ovarian cancer survivors
Despite the considerable increase in the number of QOL studies carried out in ovarian can‐
cer patients, few studies have focused, particularly, in assessing QOL in ovarian cancer sur‐
vivors. Although, ovarian cancer patients do not belong to the most prevalent survivor
population due to the aggressiveness of the disease and relatively low survival rates, it is of
utmost importance to understand the QOL of those women who live years after the diagno‐
sis without symptoms of the disease [9, 51, 52]. QOL has been evaluated namely among
small samples of survivors by using mostly the EORTC QOL-C30, EORTC QOL-OV28 and
supplemented by several other questionnaires to assess specific dimensions of QOL.
Overall, with the exception of the study conducted by Liaavaaq et al [53], available data sug‐
gests that ovarian cancer survivors have generally good QOL; however, specific deficits are
reported and these are more prevalent in ovarian cancer survivors that in women without a
history of cancer [52, 54-57]. Results concerning psychological functioning are inconsistent,
ranging from good emotional status to psychological distress, including PTSD and depres‐
sion. Below are described with more detail findings from recent studies examining QOL in
ovarian cancer survivors.
Results from the study conducted by Steward et al [54] support the view that this group of
survivors experiences overall good QOL. These investigators assessed 200 ovarian cancer
survivors, who were at the time of the study without active disease and not on treatment, on
physical, psychological and social well-being. On average, women had been diagnosed with
ovarian cancer in the previous 7 years. Results showed that the majority of the survivors
(89%) regarded their health as good or excellent. Participants also reported a better mental
health and equivalent energy levels comparing to the general population. However, the ma‐
jority of the women suffered from pelvic pain and discomfort (54%). Study findings also
demonstrated that although 57% of the survivors referred that their sexual life had been
negatively affected by the cancer and its treatment, their general sense of loss regarding sex‐
ual functioning was perceived as moderate to low. Unsurprisingly, women under 55 years
of age reported a greater sense of loss about sexual functioning and fertility. According to
these authors, the experience of surviving ovarian cancer appeared to have enriched these
women, altering their life priorities and developing on them an impressive resilience [54].
Furthermore, authors highlighted that these survivors showed in general a great pleasure in
life and relationships [54]. Similar findings were obtained in the study conducted by Wenzel
et al [55], who examined 49 early stage ovarian cancer survivors (> 5 years). Findings re‐
vealed that survivors enjoyed a good QOL, with physical, emotional and social well-being
comparable to other survivors and same aged samples without a history of cancer. Few defi‐
cits were reported, such as problems related to abdominal and gynaecological symptoms,
and neurotoxicity. In the emotional domain, scores were more variable, with only one third
of the survivors experiencing an excellent emotional well-being. Fears of future diagnostic
tests (30%) and recurrence (20%) were also found. Investigators emphasised the resilience
and growth that survivors reported in their study as a result of their ovarian cancer experi‐
ence [55]. Another attempt to understand QOL in ovarian cancer survivors was carried out
by Matulonis et al [56], who evaluated 55 early stage survivors. Findings demonstrated that
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survivors had good physical QOL, with few long-term physical symptoms (such as abdomi‐
nal complaints and neurotoxicity) and few unmet needs. However, survivors reported emo‐
tional problems, such as psychological distress (40%), anxiety about Ca125 testing (54%),
fear of recurrence (56%) and 26% had scores suggestive of PTSD. Better mental health was
associated with less fatigue and pain, fewer stressful life events and higher social support.
The authors reported as well sexual problems, namely pain during sexual intercourse (52%).
Less than 10% of participants were interested in sex or were sexually active. Additionally, it
was noted that younger survivors presented greater sexual problems. Similarly, Mirabeau-
Beale et al [57] who conducted the first comparison between early stage (58 women) and ad‐
vanced stage (42 women) survivors on QOL (> 3 years), physical, sexual and mental
function, reported that survivors experienced positive overall QOL and long-term adjust‐
ment. Investigators reported no differences between early stage and advanced stage survi‐
vors on overall QOL, unmet needs, social support, complementary therapy use, physical
symptoms (neurotoxicity, fatigue and comorbidities), functioning (cognitive, sexual, physi‐
cal, role, emotional and sexuality), spirituality, hopelessness and psychological state. How‐
ever, advanced stage survivors experienced better social functioning. Although, the majority
of survivors had a good emotional functioning, scores suggestive of PTSD were noted in 7%
of early stage survivors. Diagnosable PTSD scores were not found in the advance stage sur‐
vivors group. Decreased sexual interest attributed to cancer, physical comorbidities, such as
degenerative joint disease, gastrointestinal distress and thyroid disease, fear of recurrence,
use of complementary and alternative medicines (exercise, vitamins, prayer and massage) in
order to improve their QOL were reported by survivors. The most recent account on QOL in
ovarian cancer survivors was given by Greimel et al [52], who attempted to fill a gap in the
literature by conducting a prospective study on QOL in long-term survivors (> 10 years).
This longitudinal study examined survivors at three time points: pre-treatment (baseline), 1-
year after diagnosis and 10 years post-treatment using the EORTC QOL-C30. At the base‐
line, 33 survivors were included; of those, 22 died within 5 years post diagnosis and 11
survived beyond 10 years. In general, results corroborated previous findings reporting that
survivors experienced a good physical, psychological, social and spiritual health. Despite no
differences at baseline in FIGO stage, residual tumour, performance status and treatment
characteristics between short-term and long-term survivors, the latter group experienced
better physical functioning, role functioning, cognitive functioning and less symptoms than
short-term survivors. Higher levels of symptoms and intra operative ascites were also more
prevalent in the short-term survivors group. One year after treatment, the majority of the
QOL dimensions were comparable among the two groups; however, long-term survivors re‐
ported better global QOL but more insomnia. Emotional functioning and global QOL im‐
proved significantly from baseline to 1 year after diagnosis and remained relatively stable in
the 10 year follow-up evaluation. Long-term survivors did not experience more sleeping
problems 10 years after their diagnosis than women from a general population [52].
Contradicting the trend described above, Liaavaaq et al [53] evaluated 189 ovarian cancer
survivors (> 18 months after primary treatment) and found that survivors experienced poor‐
er QOL, had more chronic fatigue and mental morbidity, used more medication and health
services when compared to age-adjusted controls from the general population.
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Recent studies attempted to improve methodological deficits observed in previous research,
for example, by using more standardized and validate measures to assess QOL in this can‐
cer population. However, small sample sizes, heterogeneity of samples, timing of assess‐
ment are among the difficulties posed by current research, which make problematic to reach
definite conclusions. Despite this, collectively, existing studies highlight important issues
and concerns experienced by ovarian cancer survivors. Beyond the expected physical and
sexual sequalaes of the illness and treatment, studies highlighted, particularly, psychological
difficulties faced by survivors, which may adversely affect their psychological adjustment
and well-being. Findings from survivorship research are paramount to provide critical infor‐
mation to guide the development and design of interventions to assist survivors at risk.
The care provided to the cancer patient does not cease when the treatment ends. Survivor‐
ship is now recognized as a phase in the cancer trajectory that requires special attention and
ongoing specialized care. In 2006, the Institute of Medicine (IOM) published a report on can‐
cer survivorship entitled: 'From cancer patient to cancer survivor: Lost in transition' [58],
identifying unique concerns for cancer survivors, recommending the development of a sur‐
vivorship plan to be developed at the end of treatment for all people treated for cancer of
any type. Examples of requirements of the survivorship care plan as recommended by the
IOM include, among others, information on possible late and long term effects of treatments
and symptoms of such effects, information on the possible effects of cancer on marital/part‐
ner relationship, sexual functioning, work and parenting and the potential future need for
psychosocial support, referrals to specific follow-up care providers (e.g. rehabilitation, psy‐
chology), support groups, and/or the patient's primary care provider.
5. QOL in ovarian cancer: The challenges
Definitely, one of the main challenges in QOL research is to translate and apply the findings
obtained in research settings to clinical practice. In fact, in order to fully take advantage of
all the benefits offered by QOL research, it is imperative that QOL research provides health
care professionals with clinically relevant and interpretable information that can guide treat‐
ment decisions. However, routine use of QOL measures has been limited in clinical settings
[6]. Challenges of using QOL data to inform clinical practice may include the use of some‐
what arbitrary cutoff points or magnitude of change in QOL scores to determine when ther‐
apeutic change is needed [26]. To optimize treatment decisions for patients with ovarian
cancer, it is paramount that health care professionals are familiar with differences between
treatment regimens regarding toxicity, dosage and administration but also findings from
QOL measurements [11].
From the research perspective, there is a need for standardized collection and reporting of
QOL data from ovarian cancer patients, such as use of common instruments that demon‐
strate the most sensitivity to the study hypothesis and outcomes of interest, common data
collection time points, minimum expectations for data analysis and publication reporting
guidelines. These would allow comparative effectiveness research to be carried out [18]. Fur‐
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ther larger and rigorous studies are needed to fully understand QOL issues in ovarian can‐
cer patients. Longitudinal studies examining QOL across the different phases of ovarian
cancer trajectory would give valuable insights into the QOL of these patients.
As new treatment regimens for ovarian cancer continue to be developed and investigated in
the hope of improving survival of patients, it is paramount that QOL is regarded as one of
the most important endpoints in clinical trials. However, this is not sufficient. It is as well
important to routinely assess QOL disruptions in patients in clinical settings in order to
screen and identify patients at risk. Therefore, efforts should also be targeted to the develop‐
ment of interventions to be used in women at need, to prevent or ameliorate the negative
impact of the illness on QOL. The assessment of QOL in clinical settings also allows the
identification of QOL needs throughout the cancer trajectory.
6. Conclusion
Ovarian cancer patients may experience QOL disruptions and a wide range of sequalae that
do not dissipate with time and may persist for a long-term period. Measuring QOL in ovari‐
an cancer patients during the illness trajectory is of utmost importance. This is of great value
to develop and design interventions to assist ovarian cancer patients at need, and as well to
assist in the therapeutic decision process.
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